Development and Validation of Novel Models Including Tumor Micronecrosis for Predicting the Postoperative Survival of Patients With Hepatocellular Carcinoma
Sponsor study identifier
observational
765
1 country
1
Study Start
September 15, 2022
Actual (reported)Primary Completion
March 30, 2023
Actual (reported)Study Completion
December 30, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The heterogeneity of hepatocellular carcinoma (HCC) leads to the unsatisfying predicting performance of current staging systems. HCC patients with pathological tumor micronecrosis have immunosuppressive microenvironment. We aimed to develop novel prognostic models by integrating micronecrosis to more precisely predict the survival of HCC patients after hepatectomy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 30, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 15, 2022
Actual (reported)March 30, 2023
Actual (reported)April 17, 2023
Actual (reported)May 1, 2023
Actual (reported)December 30, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
the Harrell concordance index (C-index)
Up to 5 years
the time-dependent area under the receiver operating characteristic curve(tdAUROC)
Up to 5 years
HCC patients receiving curative hepatic resection
HCC patients receiving curative hepatic resection
whether HCC patients having tumor micronecrosis or not
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
This retrospective study enrolled HCC patients receiving curative hepatectomy in the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) (n = 765)
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
First Submitted
April 17, 2023
First Posted
May 1, 2023
Study Start
September 15, 2022
Actual (reported)Primary Completion
March 30, 2023
Actual (reported)Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Contact the study team to confirm eligibility.
Study Completion
December 30, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 1, 2023
Record last verified: 2023-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: